Know More

About Prolieve®

Prolieve® is a US-FDA approved Thermodilation System for treatment of Benign Prostatic Hyperplasia (BPH)

  • 45-Minute In-Office Procedure
  • No post-treatment hospitalization is necessary
  • Patient may resume normal daily activities immediately after the 45 minutes treatment
  • Treatment is the only minimally Invasive BPH treatment, demonstrating immediate symptom relief, long term efficacy, and is not associated with many undesirable side effects
  • Over 100,000 Cases Performed in the U.S.
  • Submitted 120-Month Post-Approval Study Annual Status Report to FDA. Evaluate the long-term safety and effectiveness of the Prolieve® Thermodilatation System in the treatment of BPH
  • 99% do not experience erectile dysfunction or reduction in sexual function
  • Durability 80% reported No Worsening of BPH Symptoms at 5 Years of Follow-up
  • Improvement of:
    • Mean AUA symptom score baseline 20.12 versus 12.86 at year 5
    • Peak flow rate baseline 8.55 versus 13.04 at year 5

Prolieve® Thermodilatation 120 months post market study on May 2017 to FDA according to AUASS proved:

  • Minimal Sexual side effect
  • AUASS still has 36% improvement
  • Peak flow rate still has 53% improvement
  • Stabilization of BPH symptoms, 78% reported no progression at year 5

Contact us for more information, press here